API | momelotinib

momelotinib (Ojjaara) Report issue

Small molecule Orphan Drug ^FDA Approved ^FDA

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Momelotinib, sold under the brand name Ojjaara, is an anticancer medication used for the treatment of myelofibrosis. It is a Janus kinase inhibitor and it is taken by mouth. ^Wikipedia

Chemistry

SMILES: N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
InChIKey: ZVHNDZWQTBEVRY-UHFFFAOYSA-N
Mol. Mass: 414.47
ALogP: 2.98 Partition coefficient
ChEMBL Molecules:

momelotinib

momelotinib dihydrochloride

More Chemistry

Pharmacology

Mechanisms of Action:
- Tyrosine-protein kinase JAK1 (Homo sapiens) ^UniProt
- Tyrosine-protein kinase JAK2 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Prescription Only
Delivery Methods: Oral
Pro Drug: No

cyt-11387 | cyt387 | cyt 387 | cyt-387 | gs-0387 | momelotinib | momelotinib dihydrochloride

Organizations (15)

Research & Development (15)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (6)

Approved Indications (3)

Polycythemia Vera

Primary Myelofibrosis (approved 2023)

Thrombocythemia, Essential

Experimental Indications - Clinical Trial Phases 1-4 (6)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 3)

Polycythemia Vera (Phase 3)

Primary Myelofibrosis (Phase 3)

Thrombocythemia, Essential (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 17
# of Trial Organizations: 15

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue